Women in Biotech Networking Evening - September
Women from across the sector are invited to enjoy an evening of great networking and a thought provoking talk from our guest speakers, Professor Melissa Hanna-Brown, UK/EU and Analytical Lead, Pfizer and Dr Emma Sceats, CEO, CN Bio Innovations
Setting the agenda: women leading innovation within life sciences
Continuing our celebration of ten years of Women in Biotech, we are thrilled to welcome two inspiring speakers for this evening to discuss the role of women as both intrapreneurs and entrepreneurs in the life sciences. Innovate UK’s recent infocus Women in Innovation campaign was established to challenge the low numbers of women entrepreneurs in the UK and to address some of the barriers to female entrepreneurship – lack of relevant role models and lack of confidence in applications for finance being two of them. Why do these barriers persist and how can we tackle them?
This evening will explore some of these themes, reflecting both on speakers’ personal career paths and learnings as successful innovators in life science – and also on the broader implications for the sector of the untapped potential of women in innovation, and the challenges of increasingly interdisciplinary nature of scientific discovery.
Melissa is Technology and Innovation EU Lead for Pfizer Global R&D, Visiting Professor at the Department of Chemistry at the University of Warwick and President of the Analytical Division of the Royal Society of Chemistry. Melissa’s career history has a common thread of science spanning Academic and Industrial sector. She currently works in Pfizer Pharmaceutical Sciences as the Technology and Innovation Lead for the EU, a role involving strategy development and implementation with science and business leaders across the global Pharm Sci organisation. She also spends time developing knowledge and strategy around innovation ecosystems and how they can be monitored and shaped to best influence future strategic priorities.
Melissa's previous roles in Pfizer have included Analytical Lead for cross disciplinary teams leading the charge on late development activities towards new drug applications, where she has experience representing Pfizer Pharm Sci to global regulatory agencies. The first part of Melissa’s career was as an academic in Department of Pharmacy, King’s College London where she taught Pharmaceutical Chemistry and led a research group. During this time she won an International award for Innovation (Desty) and successfully obtained funding from RCUK, EU and industrial sources.
Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses. Before joining Isogenica, Dr Sceats, was CEO of CN Bio Innovations, which she grew from a Oxford University spin-out to a recognised leader in human Organ-on-Chip technologies.
Dr Sceats was instrumental in the development and execution of CN Bio’s vision, resulting in strong revenue growth, rapid development of two innovative new products, and a pioneering partnership with the Food and Drug Administration to characterise the use of Organs-on-Chips in drug development and regulatory evaluation. Earlier in her career Emma was a technology manager at Oxford University Innovation, responsible for patenting, marketing and licensing technologies developed at the university and building spin-out companies to exploit IP.
Emma was a Presidential scholar in chemistry at the Massachusetts Institute of Technology and a graduate scholar at the University of Oxford (DPhil, Chemistry).